NASDAQ:ASND - Ascendis Pharma Stock Price, Price Target & More

$63.81 -1.20 (-1.85 %)
(As of 04/22/2018 12:06 PM ET)
Previous Close$63.81
Today's Range$63.5150 - $65.6550
52-Week Range$21.95 - $69.00
Volume71,845 shs
Average Volume112,381 shs
Market Capitalization$2.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.64

About Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma logoAscendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Debt-to-Equity RatioN/A
Current Ratio8.61%
Quick Ratio8.61%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.80 million
Price / Sales1,471.88
Cash FlowN/A
Price / CashN/A
Book Value$5.82 per share
Price / Book10.96

Profitability

EPS (Most Recent Fiscal Year)($4.33)
Net Income$-140,040,000.00
Net Margins-8,156.09%
Return on Equity-74.67%
Return on Assets-66.95%

Miscellaneous

Employees101
Outstanding Shares41,520,000

How to Become a New Pot Stock Millionaire

Ascendis Pharma (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma's stock symbol?

Ascendis Pharma trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma's earnings last quarter?

Ascendis Pharma (NASDAQ:ASND) issued its quarterly earnings results on Tuesday, May, 23rd. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.19. The biotechnology company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $1.10 million. Ascendis Pharma had a negative return on equity of 74.67% and a negative net margin of 8,156.09%. View Ascendis Pharma's Earnings History.

When is Ascendis Pharma's next earnings date?

Ascendis Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, May, 22nd 2018. View Earnings Estimates for Ascendis Pharma.

What price target have analysts set for ASND?

7 equities research analysts have issued 12 month target prices for Ascendis Pharma's shares. Their predictions range from $51.00 to $78.00. On average, they expect Ascendis Pharma's share price to reach $67.3333 in the next year. View Analyst Ratings for Ascendis Pharma.

What are Wall Street analysts saying about Ascendis Pharma stock?

Here are some recent quotes from research analysts about Ascendis Pharma stock:
  • 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (3/1/2018)
  • 2. Wedbush analysts commented, "The Wedbush View. We see ASND as an attractive investment in the short- and longer-term with pipeline progress and competitor data release in the coming months, plus results from the pivotal heiGHt trial in late 2018. Cash runway into Q4:18. Ascendis reported revenues of €0.37MM and a (loss) of €(0.78)." (5/24/2017)

Who are some of Ascendis Pharma's key competitors?

Who are Ascendis Pharma's key executives?

Ascendis Pharma's management team includes the folowing people:
  • Mr. Michael Wolff Jensen L.L.M., Chairman, Sr. VP, Gen. Counsel and Member of Exec. Board (Age 47)
  • Mr. Jan Møller Mikkelsen, Chief Exec. Officer, Pres, Member of Exec. Board and Exec. Director (Age 58)
  • Mr. Scott T. Smith, Chief Financial Officer and Sr. VP (Age 44)
  • Mrs. Lotte Sønderbjerg, Chief Admin. Officer, Sr. VP and Member of Exec. Board (Age 57)
  • Dr. Grethe Rasmussen Ph.D., Sr. VP of Product Devel. and Member of Exec. Board (Age 56)

When did Ascendis Pharma IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Has Ascendis Pharma been receiving favorable news coverage?

News stories about ASND stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ascendis Pharma earned a news sentiment score of 0.07 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Ascendis Pharma's major shareholders?

Ascendis Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include ORBIMED ADVISORS LLC (11.80%) and ORBIMED ADVISORS LLC (11.80%). View Institutional Ownership Trends for Ascendis Pharma.

How do I buy shares of Ascendis Pharma?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma's stock price today?

One share of ASND stock can currently be purchased for approximately $63.81.

How big of a company is Ascendis Pharma?

Ascendis Pharma has a market capitalization of $2.65 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma employs 101 workers across the globe.

How can I contact Ascendis Pharma?

Ascendis Pharma's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma (ASND)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ascendis Pharma (NASDAQ:ASND) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Ascendis Pharma in the last 12 months. Their average twelve-month price target is $67.3333, suggesting that the stock has a possible upside of 5.52%. The high price target for ASND is $78.00 and the low price target for ASND is $51.00. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.862.862.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $67.3333$59.8333$40.4517$36.9517
Price Target Upside: 5.52% upside6.66% downside19.48% downside0.40% downside

Ascendis Pharma (NASDAQ:ASND) Consensus Price Target History

Price Target History for Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma (NASDAQ:ASND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018WedbushReiterated RatingTop Pick$76.00HighView Rating Details
4/2/2018Leerink SwannReiterated RatingMkt Perform -> Market Perform$37.00 -> $64.00HighView Rating Details
3/21/2018JPMorgan ChaseBoost Price TargetOverweight$75.00HighView Rating Details
3/20/2018Credit Suisse GroupBoost Price TargetOutperform -> Outperform$50.00 -> $78.00HighView Rating Details
1/25/2018Bank of AmericaBoost Price TargetBuy -> Buy$45.00 -> $60.00HighView Rating Details
1/19/2018HC WainwrightReiterated RatingBuyMediumView Rating Details
9/22/2017Wells FargoReiterated RatingBuy$51.00HighView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Ascendis Pharma (NASDAQ:ASND) Earnings History and Estimates Chart

Earnings by Quarter for Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma (NASDAQ:ASND) Earnings Estimates

2018 EPS Consensus Estimate: ($3.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.95)($0.95)($0.95)
Q2 20181($0.96)($0.96)($0.96)
Q3 20181($0.98)($0.98)($0.98)
Q4 20181($1.00)($1.00)($1.00)

Ascendis Pharma (NASDAQ ASND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/22/2018        
11/16/2017Q3 2017($0.85)($1.22)$0.95 million$0.51 millionViewN/AView Earnings Details
8/18/20176/30/2017($0.80)($1.04)$0.78 million$0.44 millionViewN/AView Earnings Details
5/23/2017Q1($0.64)($0.83)$1.10 million$0.40 millionViewN/AView Earnings Details
3/22/2017Q4($0.61)($0.55)$1.22 million$1.13 millionViewN/AView Earnings Details
11/30/2016Q316($0.71)($0.80)$1.25 million$1.30 millionViewN/AView Earnings Details
8/31/2016Q216($0.67)($0.60)$1.11 million$1.28 millionViewListenView Earnings Details
5/19/2016Q1($0.55)($0.90)$1.39 millionViewN/AView Earnings Details
4/14/2016Q4 2015($0.46)($0.54)$2.17 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.57)($0.34)$2.25 million$2.37 millionViewN/AView Earnings Details
8/24/2015Q2($0.48)($0.70)$2.23 million$2.15 millionViewN/AView Earnings Details
5/18/2015Q115($0.39)$0.0670$2.24 million$2.38 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ascendis Pharma (NASDAQ:ASND) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ascendis Pharma (NASDAQ ASND) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 40.00%
Institutional Ownership Percentage: 73.48%
Insider Trading History for Ascendis Pharma (NASDAQ:ASND)
Institutional Ownership by Quarter for Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma (NASDAQ ASND) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Ascendis Pharma (NASDAQ ASND) News Headlines

Source:
DateHeadline
$300,000.00 in Sales Expected for Ascendis Pharma (ASND) This Quarter$300,000.00 in Sales Expected for Ascendis Pharma (ASND) This Quarter
www.americanbankingnews.com - April 22 at 2:36 AM
Ascendis Pharma (ASND) Expected to Announce Earnings of -$0.93 Per ShareAscendis Pharma (ASND) Expected to Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - April 20 at 3:14 PM
Ascendis Pharma (ASND) Rating Reiterated by WedbushAscendis Pharma (ASND) Rating Reiterated by Wedbush
www.americanbankingnews.com - April 20 at 11:55 AM
Ascendis Pharma (ASND) Lowered to Sell at BidaskClubAscendis Pharma (ASND) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 10:42 PM
Consolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, NewConsolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, New
www.nasdaq.com - April 11 at 10:08 AM
Q3 2018 EPS Estimates for Ascendis Pharma (ASND) Decreased by WedbushQ3 2018 EPS Estimates for Ascendis Pharma (ASND) Decreased by Wedbush
www.americanbankingnews.com - April 9 at 1:52 AM
Wired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with CirrhosisWired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis
finance.yahoo.com - April 4 at 5:05 PM
Ascendis Pharmas (ASND) Outperform Rating Reiterated at WedbushAscendis Pharma's (ASND) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - April 4 at 4:10 PM
Ascendis Pharma (ASND) Upgraded to "Buy" at ValuEngineAscendis Pharma (ASND) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 7:34 PM
Ascendis Pharma (ASND) Price Target Raised to $64.00 at Leerink SwannAscendis Pharma (ASND) Price Target Raised to $64.00 at Leerink Swann
www.americanbankingnews.com - April 2 at 10:12 AM
Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial OfficerAscendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer
globenewswire.com - April 2 at 9:57 AM
Ascendis Pharma (ASND) PT Raised to $64 at Leerink PartnersAscendis Pharma (ASND) PT Raised to $64 at Leerink Partners
www.streetinsider.com - April 2 at 9:57 AM
Ascendis Pharma A/S (ASND) Given Consensus Recommendation of "Buy" by BrokeragesAscendis Pharma A/S (ASND) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 5:28 PM
JPMorgan Chase & Co. Analysts Give Ascendis Pharma A/S (ASND) a $50.00 Price TargetJPMorgan Chase & Co. Analysts Give Ascendis Pharma A/S (ASND) a $50.00 Price Target
www.americanbankingnews.com - March 30 at 11:40 PM
Edited Transcript of ASND earnings conference call or presentation 28-Mar-18 8:30pm GMTEdited Transcript of ASND earnings conference call or presentation 28-Mar-18 8:30pm GMT
finance.yahoo.com - March 29 at 9:53 AM
Ascendis Pharma A/S Reports Full Year 2017 Financial ResultsAscendis Pharma A/S Reports Full Year 2017 Financial Results
finance.yahoo.com - March 28 at 4:24 PM
Ascendis Pharma A/S to Host Earnings CallAscendis Pharma A/S to Host Earnings Call
finance.yahoo.com - March 28 at 4:24 PM
BidaskClub Upgrades Ascendis Pharma A/S (ASND) to BuyBidaskClub Upgrades Ascendis Pharma A/S (ASND) to Buy
www.americanbankingnews.com - March 27 at 4:00 PM
JPMorgan Chase & Co. Raises Ascendis Pharma A/S (ASND) Price Target to $75.00JPMorgan Chase & Co. Raises Ascendis Pharma A/S (ASND) Price Target to $75.00
www.americanbankingnews.com - March 21 at 6:06 PM
Ascendis Pharma (ASND) PT Raised to $75 at JPMorgan; Pipeline Updates Increase Our ConfidenceAscendis Pharma (ASND) PT Raised to $75 at JPMorgan; 'Pipeline Updates Increase Our Confidence'
www.streetinsider.com - March 21 at 10:39 AM
Ascendis Pharma A/S (ASND) Set to Announce Earnings on WednesdayAscendis Pharma A/S (ASND) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 21 at 2:14 AM
Ascendis Pharma A/Ss (ASND) Hold Rating Reaffirmed at Credit Suisse GroupAscendis Pharma A/S's (ASND) Hold Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - March 20 at 11:58 AM
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018
finance.yahoo.com - March 19 at 9:41 AM
$580,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter$580,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter
www.americanbankingnews.com - March 19 at 4:16 AM
-$0.92 Earnings Per Share Expected for Ascendis Pharma A/S (ASND) This Quarter-$0.92 Earnings Per Share Expected for Ascendis Pharma A/S (ASND) This Quarter
www.americanbankingnews.com - March 17 at 1:30 PM
Ascendis Pharma A/S (ASND) Given Consensus Rating of "Buy" by AnalystsAscendis Pharma A/S (ASND) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 7 at 5:51 PM
73,771 Shares in Ascendis Pharma A/S (ASND) Purchased by University of Notre Dame DU Lac73,771 Shares in Ascendis Pharma A/S (ASND) Purchased by University of Notre Dame DU Lac
www.americanbankingnews.com - March 6 at 3:40 PM
Ascendis Pharma A/S (ASND) Holdings Trimmed by VHCP Management II LLCAscendis Pharma A/S (ASND) Holdings Trimmed by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 10:50 AM
Emory University Trims Holdings in Ascendis Pharma A/S (ASND)Emory University Trims Holdings in Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 4 at 2:59 PM
Ascendis Pharma A/S (ASND) Stock Rating Upgraded by Zacks Investment ResearchAscendis Pharma A/S (ASND) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 1 at 6:36 PM
Wedbush Research Analysts Decrease Earnings Estimates for Ascendis Pharma A/S (ASND)Wedbush Research Analysts Decrease Earnings Estimates for Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 1 at 7:20 AM
Ascend Capital LLC Purchases New Stake in Ascendis Pharma A/S (ASND)Ascend Capital LLC Purchases New Stake in Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 1 at 4:42 AM
Research Analysts Issue Forecasts for Ascendis Pharma A/Ss FY2022 Earnings (ASND)Research Analysts Issue Forecasts for Ascendis Pharma A/S's FY2022 Earnings (ASND)
www.americanbankingnews.com - February 28 at 4:50 PM
Ascendis Pharma A/S (ASND) Expected to Announce Earnings of -$0.89 Per ShareAscendis Pharma A/S (ASND) Expected to Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - February 28 at 1:40 PM
Ascendis Pharma A/S (ASND) Rating Reiterated by WedbushAscendis Pharma A/S (ASND) Rating Reiterated by Wedbush
www.americanbankingnews.com - February 26 at 4:20 PM
Ascendis Pharma A/S (ASND) Stock Rating Reaffirmed by Credit Suisse GroupAscendis Pharma A/S (ASND) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - February 25 at 12:49 PM
Ascendis prices ADS offering at $57Ascendis prices ADS offering at $57
seekingalpha.com - February 22 at 4:50 PM
Ascendis Pharma A/S (ASND) Rating Increased to Hold at Zacks Investment ResearchAscendis Pharma A/S (ASND) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 21 at 6:04 PM
BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSSBRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS
www.reuters.com - February 20 at 4:52 PM
Ascendis Pharma launches $150M equity offeringAscendis Pharma launches $150M equity offering
seekingalpha.com - February 20 at 4:52 PM
Ascendis Pharma A/S (ASND) Expected to Announce Quarterly Sales of $570,000.00Ascendis Pharma A/S (ASND) Expected to Announce Quarterly Sales of $570,000.00
www.americanbankingnews.com - February 13 at 1:56 AM
 Brokerages Expect Ascendis Pharma A/S (ASND) to Post -$0.89 EPS Brokerages Expect Ascendis Pharma A/S (ASND) to Post -$0.89 EPS
www.americanbankingnews.com - February 11 at 9:18 PM
Ascendis Pharma A/S Announces Participation in Leerink Partners 7th Annual Global Healthcare ConferenceAscendis Pharma A/S Announces Participation in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 4:24 PM
Ascendis Pharma A/S (ASND) Stock Rating Reaffirmed by WedbushAscendis Pharma A/S (ASND) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - February 6 at 10:30 PM
Ascendis Pharma A/S (ASND) Raised to Strong-Buy at BidaskClubAscendis Pharma A/S (ASND) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - January 28 at 10:00 AM
 Brokerages Anticipate Ascendis Pharma A/S (ASND) Will Announce Quarterly Sales of $570,000.00 Brokerages Anticipate Ascendis Pharma A/S (ASND) Will Announce Quarterly Sales of $570,000.00
www.americanbankingnews.com - January 27 at 1:04 AM
Ascendis Pharma A/S (ASND) Expected to Post Earnings of -$0.89 Per ShareAscendis Pharma A/S (ASND) Expected to Post Earnings of -$0.89 Per Share
www.americanbankingnews.com - January 25 at 9:20 PM
Ascendis Pharma A/S (ASND) Price Target Increased to $60.00 by Analysts at Bank of AmericaAscendis Pharma A/S (ASND) Price Target Increased to $60.00 by Analysts at Bank of America
www.americanbankingnews.com - January 25 at 7:29 PM
Ascendis Pharma A/S (ASND) Stock Rating Reaffirmed by HC WainwrightAscendis Pharma A/S (ASND) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - January 19 at 8:04 PM
Ascendis Pharma A/S (ASND) Stock Rating Reaffirmed by JPMorgan Chase & Co.Ascendis Pharma A/S (ASND) Stock Rating Reaffirmed by JPMorgan Chase & Co.
www.americanbankingnews.com - January 17 at 1:34 PM

SEC Filings

Ascendis Pharma (NASDAQ:ASND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ascendis Pharma (NASDAQ:ASND) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ascendis Pharma (NASDAQ ASND) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.